281 research outputs found

    Yoctosecond metrology through HBT correlations from a quark-gluon plasma

    Full text link
    Expansion dynamics at the yoctosecond timescale affect the evolution of the quark gluon plasma (QGP) created in heavy ion collisions. We show how these dynamics are accessible through Hanbury Brown and Twiss (HBT) intensity interferometry of direct photons emitted from the interior of the QGP. A detector placed close to the beam axis is particularly sensitive to early polar momentum anisotropies of the QGP. Observing a modification of the HBT signal at the proposed FoCal detector of the LHC ALICE experiment would allow to measure the isotropization time of the plasma and could provide first experimental evidence for photon double pulses at the yoctosecond timescale.Comment: 5 pages, 3 figure

    A jövõ aszimmetrikus hadviselése

    Get PDF

    "A nemzet könyvtára - a szolgálat műhelye" : az Országos Széchényi Könyvtár Múzeumáról

    Get PDF

    A szellőcsókra...

    Get PDF

    Subcutaneously administered Menopur(R), a new highly purified human menopausal gonadotropin, causes significantly fewer injection site reactions than Repronex(R) in subjects undergoing in vitro fertilization

    Get PDF
    BACKGROUND: The safety and tolerability of a new highly purified, urine-derived human menopausal gonadotropin (hMG) preparation [Menopur(R)] was compared with a currently available hMG [Repronex (R)] in women undergoing in vitro fertilization (IVF). METHODS: This was a randomized, open-label, parallel-group, multicenter study conducted in subjects undergoing IVF. Women (N = 125), 18–39 years of age, underwent pituitary down-regulation with leuprolide acetate beginning 7 days prior to onset of menses and continuing up to the day before hCG administration. Subjects were randomized to receive subcutaneous (SC) Menopur (R) (n = 61) or Repronex (R) SC (n = 64) for a maximum of 12 days. All adverse events (AEs) were recorded and subject self-assessments of injection site reactions were recorded in a daily diary. RESULTS: Significantly fewer subjects in the Menopur (R) group reported injection site reactions (P < 0.001) compared to the Repronex (R) group. Overall, there was no statistically significant difference in the incidence of AEs between the two treatment groups. CONCLUSION: Menopur (R) SC offers a greater safety and tolerability profile compared to Repronex (R) SC
    • …
    corecore